Sort   by:  
 Page size 
UnknownEfficacy and Safety of Biosimilar CT-P47 Versus Reference Tocilizumab: 1-Year Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study in Patients with Rheumatoid Arthritis.
Not available
S-EPMC12307557 | biostudies-literature
UnknownEfficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47.
Not available
S-EPMC11492937 | biostudies-literature
Sort   by:  
 Page size